TB-500: What the Research Says
Regulatory notice: TB-500 is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. PepScribe does not currently offer TB-500 and has no confirmed timeline for availability. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including TB-500. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that TB-500's legal status has changed or that PepScribe will offer it in the future.
What is TB-500?
TB-500 is a synthetic version of a naturally occurring 43-amino-acid peptide fragment of thymosin beta-4 (Tβ4), a protein found in virtually all human and animal cells. Thymosin beta-4 was first isolated in 1981 by Allan Goldstein and colleagues at George Washington University, and it remains one of the most abundant intracellular proteins, playing a central role in cell motility, migration, and differentiation.
The research interest in TB-500 stems from its parent protein's role in wound healing and tissue repair. Unlike many peptides that target a single receptor, TB-500 works through a structural protein (actin) that's involved in how cells move and organize themselves — which is why the research spans muscle, cardiac, and dermal tissue repair.
How it works (proposed mechanisms)
Actin sequestration and polymerization
Research published by Safer et al. (1991, PNAS) established that thymosin beta-4 is the primary actin-sequestering protein in mammalian cells. TB-500 upregulates actin, the structural protein that forms the framework for cell movement. By promoting actin polymerization, it may enable cells to migrate to sites of injury more effectively — a fundamental step in tissue repair.
Cell motility promotion
A 2004 study by Malinda et al. in the Journal of Investigative Dermatology demonstrated that thymosin beta-4 promotes the migration of endothelial cells and keratinocytes to wound sites. This cell-migration effect is thought to be a primary driver of the healing-support properties observed in animal models.
Inflammation reduction
Research by Sosne et al. (2007, Expert Opinion on Biological Therapy) reported that thymosin beta-4 reduces inflammatory markers including TNF-alpha and IL-1beta at injury sites in animal models. The anti-inflammatory effect appears to complement its tissue-repair properties rather than acting through a separate pathway.
Cell differentiation
Work by Bock-Marquette et al. (2004, Nature) demonstrated that thymosin beta-4 activates cardiac progenitor cells in mouse models after myocardial infarction. The finding suggests it may promote differentiation of stem and progenitor cells at injury sites, supporting tissue regeneration over scar formation.
These mechanisms are based on preclinical and animal research. Human clinical trial data for TB-500 remains limited. None of these mechanisms have been confirmed through large-scale human trials.
What the research suggests
Most TB-500 / thymosin beta-4 research is in animal models. The parent protein has been studied more extensively than the synthetic fragment. Here's what the preclinical evidence shows.
Muscle repair
A 2010 study by Dube et al. in Annals of the New York Academy of Sciences showed that thymosin beta-4 treatment improved muscle fiber regeneration in a mouse cardiotoxin injury model. Rat models by the same group showed improved recovery of muscle function following crush and laceration injuries compared to controls. Human muscle-repair trials have not been published.
Cardiac tissue
The landmark 2004 study by Bock-Marquette et al. published in Nature demonstrated that thymosin beta-4 improved cardiac function and reduced scar size in mouse models of myocardial infarction. A follow-up by Smart et al. (2007, Nature) showed Tβ4 reactivated adult cardiac progenitor cells. These findings led to early human investigation, though translation to clinical therapy remains unproven.
Dermal wound healing
Philp et al. (2004, Wound Repair and Regeneration) published the first comprehensive study of thymosin beta-4 in dermal wound healing, reporting accelerated wound closure through combined effects on cell migration, collagen deposition, and angiogenesis in rat models. RegeneRx Biopharmaceuticals conducted Phase II trials of a Tβ4-based eye drop (RGN-259) for dry eye, one of the few human clinical applications.
Flexibility and joint health
Preclinical research by Goldstein et al. (published across multiple papers in Annals of the New York Academy of Sciences, 2007–2012) suggests thymosin beta-4 may improve joint mobility through effects on connective tissue repair and inflammation reduction. Anecdotal reports from the athletic community are extensive, but controlled human data specifically for joint health is lacking.
Administration (research context)
In published research, TB-500 has been primarily studied via subcutaneous injection. Some research protocols use twice-weekly dosing during a “loading” phase followed by less frequent maintenance, though no standardized human dosing protocol exists.
Dosing in animal research varies by study, species, and target tissue. There are no established human dosing guidelines from regulatory-grade clinical trials.
This is research context, not prescribing guidance. PepScribe does not currently offer TB-500 and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations
The safety data on TB-500 in humans is limited. Here's the honest picture.
Reported in anecdotal use
- •Headache
- •Nausea
- •Localized redness or irritation at injection site
- •Temporary lethargy or fatigue
Limited human safety data
No large-scale human safety trials have been published for TB-500 specifically. The parent protein thymosin beta-4 has more human data — RegeneRx's Phase II trials for the topical eye drop (RGN-259) reported a favorable safety profile. However, systemic TB-500 safety information comes primarily from animal toxicology studies and self-reported anecdotal use. This is a real limitation.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status
TB-500 is on the FDA's Category 2 list of bulk drug substances. Licensed compounding pharmacies in the United States cannot legally prepare or dispense it as of April 2026.
The February 27, 2026 HHS announcement about potential peptide reclassification may include TB-500, but that announcement has no legal force until formally published in the Federal Register. The legal status today is clear: TB-500 cannot be legally compounded.
Gray-market vendors sell products labeled as TB-500, but these are unregulated research chemicals without pharmaceutical-grade quality assurance.
While TB-500 isn't available, these physician-prescribed options may support similar recovery goals
Recovery, tissue support, and growth hormone optimization — through legally available, pharmacy-compounded peptides prescribed by a licensed clinician.
Sermorelin
Growth hormone-releasing peptide for recovery and body composition support. Stimulates your body's own GH production for improved recovery, sleep quality, and lean body mass. Physician-prescribed.
Get started →NAD+
Supports cellular energy, DNA repair, and the recovery processes that decline with age. NAD+ is fundamental to mitochondrial function and tissue maintenance. Physician-prescribed.
Get started →Get notified when TB-500 becomes available
Be the first to know when TB-500 becomes available through PepScribe. We'll email you when TB-500 becomes legally available through compounding pharmacies — no spam, no selling your data.
We're building the clinical and pharmacy infrastructure now so we can offer TB-500 from day one of reclassification.
Deep dives on TB-500
Research-backed articles covering specific topics in depth.